101MS408 Multicenter study of Natalizumab v Fingolimod in MS

• Research type

  Research Study

• Full title

  A Multicentre, Randomised, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects

• IRAS ID

  163087

• Contact name

  James Overell

• Contact email

  james.overell@glasgow.ac.uk

• Sponsor organisation

  Biogen Idec Limited

• Eudract number

  2013-004622-29

• Research summary

  This study explores the effect of natalizumab compared to fingolimod on central nervous system (CNS) tissue destruction, and recovery, in previously untreated Relapsing-Remitting Multiple Sclerosis (RRMS) subjects and RRMS Subjects previously treated with Betaseron, Rebif, Avonex, Copaxone, and Extavia (BRACE), with ongoing clinical and radiological disease activity.

• REC name

  West of Scotland REC 1

• REC reference

  14/WS/1105

• Date of REC Opinion

  20 Nov 2014

• REC opinion

  Further Information Favourable Opinion